Insilico Biotechnology
- Company typePrivate
- Founded2002
- HeadquartersStuttgart, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Insilico Biotechnology firmographics
Firmographics- Name
- Insilico Biotechnology
- Legal name
- Yokogawa Insilico Biotechnology GmbH
- Website
- https://insilico-biotechnology.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Insilico Biotechnology industry classification
Industry- Product category
- Bioprocess Biosimulation Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)
- akta.pro secondary industry
- Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)
Keywords
Where Insilico Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Stuttgart
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Insilico Biotechnology business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Biosimulation Software and Services: Insilico Biotechnology generates revenue through biosimulation software solutions and related consulting services for biopharmaceutical companies. The company offers computational biology tools for process development, including Digital Twin platforms and hybrid modeling solutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Insilico Biotechnology product offering
Product offeringCore offering
Insilico Biotechnology develops and licenses the Insilico Technology Platform, a computational biosimulation software for biopharmaceutical process development and biomanufacturing. The platform applies Digital Twin technology and hybrid models that combine mechanistic, first-principles models with data-driven machine learning to enable predictive simulation of cell culture processes, metabolic flux analysis, and clone selection for CHO-based biologics production. The company also delivers related biosimulation consulting services to biopharma clients.
Product overview
Insilico Biotechnology offers a unified technology platform for computational biology and biosimulation solutions focused on biopharmaceutical manufacturing. The Insilico Technology Platform enables process development and optimization through predictive digital twins, hybrid models integrating mechanistic knowledge with data-driven approaches, and systems biology modeling. The company specializes in metabolic modeling, gene regulatory network inference, and metabolic flux analysis for mammalian cells, particularly for CHO cell cultivation optimization and bioprocess design.
Differentiator
Problem solved
Functional benefit
Products and services
- Insilico Technology Platform A computational biosimulation platform for biopharmaceutical process development and manufacturing that uses predictive Digital Twins and hybrid models combining mechanistic know-how with data-driven machine learning. It enables process development and optimization, metabolic flux analysis, gene regulatory network inference, and clone selection for mammalian cell culture systems such as CHO. Targeted at biopharmaceutical and biotech companies developing and manufacturing biologics.
- Biosimulation Consulting Services Related consulting and computational biology services supporting the application of the Insilico Technology Platform, including custom modeling, process optimization, and metabolic analysis engagements for biopharmaceutical clients.
Quantifiable outcome
- High-confidence predictions in systems biology dynamic models demonstrated through peer-reviewed publications
Companies that use Insilico Biotechnology
Customer profileSegments1 record
Ideal customer profiles1 record
Insilico Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Insilico Biotechnology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- YokogawacoreInsilico Biotechnology operates as Yokogawa Insilico Biotechnology GmbH, indicating a parent-subsidiary relationship. Yokogawa, a Japanese industrial automation and control company, appears to own/control Insilico Biotechnology as part of its life sciences and biotechnology portfolio expansion.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
Insilico Biotechnology competitors and assessment
Company assessmentOthers
- Intrexon (now Precigen): Precigen's bioprocess and cell-engineering work involves modeling and optimization of cell lines relevant to Insilico's CHO and metabolic flux focus; relevant thematically as a potential customer/partner rather than a direct competitor.
Broad incumbents
- Siemens (gPROMS / Siemens Process Systems Engineering): Siemens's PSE gPROMS platform is a leading mechanistic process-modeling environment used across pharma and biopharma for process simulation, scale-up, and digital twin applications. It directly competes with Insilico's first-principles + hybrid modeling stack in bioprocess development.
- Dassault Systèmes (BIOVIA): Dassault's BIOVIA portfolio offers molecular modeling, biologics discovery, and process simulation for life sciences. Its biopharma modeling capabilities overlap with Insilico's biosimulation and digital twin offerings for biologics manufacturers.
- Cytiva (formerly GE Biopharma): Cytiva supplies a broad suite of bioprocess tools, software, and services including process modeling and digital biomanufacturing solutions. Its comprehensive bioprocess portfolio competes with Insilico across enterprise biopharma customers.
Direct peers
- Sartorius (Umetrics / SIMCA): Sartorius's Umetrics division (MODDE, SIMCA) provides DoE and multivariate analytics for bioprocess development, directly competing with Insilico's bioprocess modeling and clone-selection workflow tools for CHO and other cell lines.
- Genedata: Genedata supplies enterprise scientific informatics platforms for biopharma R&D and bioprocess development. Its focus on data-driven biologics workflows makes it a direct peer in the biopharma modeling and process informatics category.
Emerging players
- Riffyn: Riffyn offers a cloud-based scientific process data system for bioprocess R&D, with a focus on structured experimental data and reproducibility. It overlaps with Insilico's bioprocess digital twin and hybrid modeling approach from a complementary angle.
Regional players
- Atolcd (formerly ATO), a Yokogawa group ecosystem player: Closely associated with the Yokogawa ecosystem, this peer serves process development and bioprocess software needs in adjacent geographies, offering comparable biomanufacturing informatics capabilities to Insilico.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Insilico Biotechnology social profiles
Digital presenceInsilico Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Insilico Biotechnology leadership team
Management profileNumber of profiles
Insilico Biotechnology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Insilico Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Insilico Biotechnology
What does Insilico Biotechnology do?
Insilico Biotechnology develops and licenses the Insilico Technology Platform, a computational biosimulation software for biopharmaceutical process development and biomanufacturing. The platform applies Digital Twin technology and hybrid models that combine mechanistic, first-principles models with data-driven machine learning to enable predictive simulation of cell culture processes, metabolic flux analysis, and clone selection for CHO-based biologics production. The company also delivers related biosimulation consulting services to biopharma clients.
Is Insilico Biotechnology a public or private company?
Insilico Biotechnology is a private company. It is classified as corporate owned and is currently operating.
When was Insilico Biotechnology founded?
Insilico Biotechnology was founded in 2002. It employs 11 to 50 people.
Where is Insilico Biotechnology based?
Insilico Biotechnology is headquartered in Stuttgart, Germany, in the Europe region.
How does Insilico Biotechnology make money?
One revenue line is on record: biosimulation Software and Services.
Who are Insilico Biotechnology's main competitors?
Intrexon (now Precigen) is listed as an others. Broad incumbents are Siemens (gPROMS / Siemens Process Systems Engineering), Dassault Systèmes (BIOVIA) and Cytiva (formerly GE Biopharma). Direct peers are Sartorius (Umetrics / SIMCA) and Genedata. Riffyn is listed as an emerging player. Atolcd (formerly ATO), a Yokogawa group ecosystem player is listed as a regional player.
Does Insilico Biotechnology have an API?
No public API is recorded for Insilico Biotechnology.
What industry is Insilico Biotechnology in?
Insilico Biotechnology's product category is Bioprocess Biosimulation Software. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of HLAAAJAE, Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES). Its NAICS code is 541714 and its SIC code is 8731.